1. Cumulative live birth rates in low-prognosis women
- Author
-
Harold R. Verhoeve, Egbert A. Brinkhuis, Simone C Oudshoorn, Marcel H.A van Hooff, Joop S.E. Laven, G.J. Scheffer, Ben W.J. Mol, Jan Bruin, Annemiek W. Nap, Monique H. Mochtar, G. Jur E. Oosterhuis, Marinus J.C. Eijkemans, Ron J. T. van Golde, Theodora C. van Tilborg, Walter K. H. Kuchenbecker, Janet Kwee, Frank J.M. Broekmans, Kathrin Fleischer, Evert J.P. van Santbrink, A. Petra Manger, Annemieke Hoek, Carolien A.M. Koks, Cornelis B. Lambalk, Jori A Leijdekkers, Corry H. Dekoning, Jesper M. J. Smeenk, Madelon van Wely, Helen L. Torrance, Alexander V. Sluijmer, Bendictus C. Schoot, Jaap Friederich, Arie Verhoeff, Henk Groen, Graduate School, Center for Reproductive Medicine, ARD - Amsterdam Reproduction and Development, Amsterdam Reproduction & Development (AR&D), Obstetrics and gynaecology, ACS - Atherosclerosis & ischemic syndromes, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Cardiology, Obstetrics & Gynecology, Obstetrie & Gynaecologie, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), RS: GROW - R4 - Reproductive and Perinatal Medicine, Reproductive Origins of Adult Health and Disease (ROAHD), and Value, Affordability and Sustainability (VALUE)
- Subjects
GNRH AGONIST ,STIMULATION ,medicine.medical_specialty ,anti-Mullerian hormone ,Cost effectiveness ,Reproductive medicine ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,ovarian reserve ,OVARIAN RESPONSE ,POOR RESPONSE ,COST-EFFECTIVENESS ,03 medical and health sciences ,cumulative live birth ,0302 clinical medicine ,HORMONE ,Obstetrics and gynaecology ,poor ovarian response ,medicine ,Cumulative incidence ,Ovarian reserve ,030304 developmental biology ,0303 health sciences ,030219 obstetrics & reproductive medicine ,business.industry ,IVF/ICSI ,Rehabilitation ,STARTING IVF/ICSI ,Obstetrics and Gynecology ,ovarian stimulation ,3. Good health ,Clinical trial ,POSEIDON criteria ,female age ,Bologna criteria ,anti-Müllerian hormone ,Reproductive Medicine ,IVF ,Infertility ,low prognosis ,Original Article ,Live birth ,business ,IN-VITRO FERTILIZATION ,ANTRAL FOLLICLE COUNT ,Cohort study ,Demography - Abstract
STUDY QUESTION: Do cumulative live birth rates (CLBRs) over multiple IVF/ICSI cycles confirm the low prognosis in women stratified according to the POSEIDON criteria? SUMMARY ANSWER: The CLBR of low-prognosis women is ~56% over 18 months of IVF/ICSI treatment and varies between the POSEIDON groups, which is primarily attributable to the impact of female age. WHAT IS KNOWN ALREADY: The POSEIDON group recently proposed a new stratification for low-prognosis women in IVF/ICSI treatment, with the aim to define more homogenous populations for clinical trials and stimulate a patient-tailored therapeutic approach. These new criteria combine qualitative and quantitative parameters to create four groups of low-prognosis women with supposedly similar biologic characteristics. STUDY DESIGN, SIZE, DURATION: This study analyzed the data of a Dutch multicenter observational cohort study including 551 low-prognosis women, aged
- Published
- 2019
- Full Text
- View/download PDF